April 2020, Volume 6, Issue 5

April 2020

Volume 6, Issue 5

This issue examines immunization guidelines for patients with hematologic disorders, considers medical education amid the coronavirus pandemic, and more.

Table of Contents

April 2020 Issue

You Make the Call

Reader Responses: How would you treat a frail patient with relapsed hairy cell leukemia variant?

Wednesday, April 1st, 2020
Here’s how readers responded to a You Make the Call question about treatment of early-relapsing hairy cell leukemia variant. Disclaimer: ASH does not recommend or...

Leukemia’s Collision With Souls and Soulcraft

Wednesday, April 1st, 2020
In this edition, Jason Gotlib, MD, MS, reviews When Blood Breaks Down: Life Lessons from Leukemia by Mikkael Sekeres, MD, MS, which explores how...

COVID-19: The Global Disrupter of Medical Education

Wednesday, April 1st, 2020
On January 7, health officials confirmed that cases of pneumonia in Wuhan, China, which Chinese authorities had notified the World Health Organization about in...

April 2020 Issue

Can Dasatinib Overcome the Negative Effects of KIT Mutations in Core Binding Factor AML?

Wednesday, April 1st, 2020
A chemotherapy regimen of cytarabine and daunorubicin plus dasatinib was well tolerated in patients with previously untreated core binding factor acute myeloid leukemia (CBF-AML)...

Metabolic Syndrome Predicts Risk of Recurrent VTE in Patients With Newly Diagnosed DVT

Wednesday, April 1st, 2020
Patients with newly diagnosed deep vein thrombosis (DVT) who have components of metabolic syndrome – hypertension, hyperlipidemia, diabetes mellitus, or obesity – have a...

FDA Grants Breakthrough Designation to APR-246 for MDS

Wednesday, April 1st, 2020
The FDA granted breakthrough therapy designation to APR-246 in combination with azacitidine for the treatment of patients with myelodysplastic syndromes (MDS) and a TP53...

FDA Asks Manufacturer to Withdraw Diet Drug Over Cancer Risk

Wednesday, April 1st, 2020
The FDA issued a safety communication asking Eisai Co. to voluntarily recall its weight management drug lorcaserin, a selective activator of 5-HT2C serotonin receptors...
WIB_icon

Higher Altitudes, Higher Hemoglobin: Mapping Switzerland’s Topography and Hemoglobin Levels

Wednesday, April 1st, 2020
Even small increases in residential altitude significantly elevated blood hemoglobin (Hb) and ferritin levels in young men living in Switzerland, according to a study...
WIB_icon

Germline RUNX1 Mutations in RUNX1-Mutated AML More Frequent Than Previously Thought

Wednesday, April 1st, 2020
A small study in Canada shows that the frequency of germline RUNX1 mutations in patients with RUNX1-mutated acute myeloid leukemia (AML) is higher than...
WIB_icon

Patients With SCD and TP53 Mutations May Develop Myeloid Malignancy After Unsuccessful AlloHCT

Wednesday, April 1st, 2020
Population studies have shown that patients with sickle cell disease (SCD) who have undergone an unsuccessful allogeneic hematopoietic cell transplantation (alloHCT) have an increased...
The Society Pages

Remembering Clara Bloomfield, City of Hope Appoints Eileen Smith as Head of Hematology, and...

Wednesday, April 1st, 2020
Remembering Clara Bloomfield, MD (1942 – 2020) Leukemia scientist Clara Bloomfield, MD, died on March 1, 2020 at the age of 77. With more than 50...

Hemophilia A Gene Therapy Offers Sustained Clinical Benefit

Wednesday, April 1st, 2020
In men with severe hemophilia A, treatment with an adeno-associated virus serotype 5 (AAV5) vector containing a B-domain-deleted factor VIII (FVIII) gene, known as...

Tazemetostat Granted Priority Review for Relapsed/Refractory Follicular Lymphoma

Wednesday, April 1st, 2020
The FDA granted a priority review to the new drug application (NDA) for tazemetostat for the treatment of patients with relapsed or refractory follicular...

CAR T-Cell Therapy KTE-X19 Granted Priority Review for MCL

Wednesday, April 1st, 2020
The FDA granted priority-review designation to the investigational chimeric antigen receptor (CAR) T-cell therapy KTE-X19 for the treatment of adults with relapsed or refractory...

2021 Budget Proposal Cuts Funding for CDC, NIH, and CMS

Wednesday, April 1st, 2020
The Trump administration issued its proposed budget for the 2021 fiscal year, which contains substantial cuts to several federal health-care agencies, including the Centers...
ASH Directions

Nominate Yourself or a Colleague for an ASH Leadership Position, and more

Wednesday, April 1st, 2020
Clinical Practitioners: Nominate Yourself or a Colleague for an ASH Leadership Position American Society of Hematology (ASH) members in good standing can nominate themselves or...

HCT Recipients Acquire Rare, Potentially Harmful Clonal Mutations Harbored by Younger Donors

Wednesday, April 1st, 2020
Some patients with acute myeloid leukemia (AML) who received a hematopoietic cell transplantation (HCT) from young donors acquired rare, yet potentially harmful, clonal mutations...
WIB_icon

Blinatumomab Leads to High Remission Rate in Infants With Persistent MRD-Positive ALL

Wednesday, April 1st, 2020
Treatment with the bispecific CD19/CD3 antibody blinatumomab induced molecular remissions in most infants with persistent measurable residual disease (MRD)–positive acute lymphocytic leukemia (ALL), according...

April 2020 Issue

The Who, What, and When of Immunizations

Wednesday, April 1st, 2020
As the world scrambles to find a vaccine for the newest coronavirus, appropriate use of existing vaccines remains vital for immunosuppressed patients. Current vaccination...

Pulling Back the Curtain: Georgette Dent, MD

Wednesday, April 1st, 2020
In this edition, Georgette Dent, MD, talks about pathology, public service, and the power of education. Where did you grow up? What was your childhood...

April 2020 Issue

You Make the Call

You Make the Call: How would you treat a frail patient with relapsed hairy cell...

Wednesday, April 1st, 2020
This month, Marty Tallman, MD, discusses treatment of early-relapsing hairy cell leukemia variant. And don't forget to check out next month's clinical dilemma - send...